Norzyme Inc. is a biotechnology company providing a significant technology breakthrough in the areas of new therapeutic drug monitoring and high throughput screening. Norzyme has developed a revolutionary, patent-pending technology that will provide the Clinical, Pharmaceutical, Research and direct Physician Markets with accurate and cost-effective test kits for the detection and measurement of protease inhibitors in HIV patients, critically important information that enables clinicians to prescribe proper amounts of drugs to HIV-AIDS patients and monitor drug resistance. The company recently received an initial grant from the National Institute of Health and currently is on track for FDA submission by end of 2001. Dr. Ron Marquardt, PhD., and Dr. Zhibo Gan, PhD., who developed the Norzyme technology at the University of Manitoba, Canada, remain active members of the Chicago-based company
